Related Experiment Video

Updated: Jul 18, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and

Mohamed A Soltan1, Ahmad A Alhanshani2, Ayed A Shati2

  • 1Department of Microbiology and Immunology, Faculty of Pharmacy, Sinai University, Ismailia 41611, Egypt.

Biomedicines
|August 26, 2023
PubMed

Insights

The Cyclin dependent kinase inhibitor 2A (CDKN2A) gene, often a tumor suppressor, is upregulated in cancers. Its alterations impact immune cells and predict tumor progression and patient survival across various cancer types.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Cyclin dependent kinase inhibitor 2A (CDKN2A) is a known tumor suppressor gene regulating the cell cycle.
  • Existing research links CDKN2A malfunction to human tumor initiation and progression.
  • A comprehensive pan-cancer analysis of CDKN2A's effect on immune components and patient outcomes is lacking.

Purpose of the Study:

  • To analyze CDKN2A differential expression in tumors versus normal tissues.
  • To correlate CDKN2A alterations with tumor stage, grade, metastasis, and clinical outcomes.
  • To assess the impact of CDKN2A genetic alterations on human immune components in a pan-cancer model.

Main Methods:

  • Differential expression analysis of CDKN2A in tumor and normal tissues.
  • Profiling of CDKN2A genetic alterations in tumor conditions.
  • Correlation analysis between CDKN2A status and immune cell infiltration (CD8, CCL4, CCR6).

Main Results:

  • CDKN2A was found to be upregulated in cancerous tissues compared to normal tissues.
  • Increased CDKN2A expression correlated with advanced tumor stage, grade, and metastasis.
  • CDKN2A alterations influenced the infiltration and status of CD8 T-cells, CCL4, and CCR6.

Conclusions:

  • CDKN2A upregulation predicts poor prognosis in multiple human cancers.
  • CDKN2A genetic alterations affect key immune components, influencing tumor progression.
  • CDKN2A alterations show potential as prognostic and immunological biomarkers in various cancers.
Keywords:
CDKN2Adifferential expressionepigenetic alterationgenetic alterationimmunotherapypatient survival

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

423
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K